Literature DB >> 18762713

Effects of angiotensin II receptor blockers on renal handling of uric acid in rats.

Yan Li1, Masanobu Sato, Yuichi Yanagisawa, Hideaki Mamada, Akimasa Fukushi, Kentaro Mikami, Yoshiyuki Shirasaka, Ikumi Tamai.   

Abstract

Elevated serum uric acid level has been associated with increased cardiovascular risk in hypertensive patients. Several angiotensin II receptor blockers exhibit differential effects on regulation of serum uric acid level in humans. We have demonstrated that some angiotensin II receptor blockers trans-stimulate the uptake of uric acid by human URAT1 and others inhibit the transport of uric acid mediated by human URAT1, OAT1, OAT3 and MRP4 in vitro. This study investigated the effects of candesartan, pratosartan and telmisartan on renal handling of uric acid in rats in vivo and in vitro. Candesartan (0.1 mg/kg) significantly decreased the urinary excretion of uric acid and increased the plasma uric acid concentration. The kidney candesartan level after low-dose treatment is close to that required to trans-stimulate uric acid uptake in vitro. Pratosartan exhibited dose-dependent hypouricemic and uricosuric effects, while telmisartan showed no effects on plasma uric acid level. Furthermore, we confirmed the effects of the tested drugs on uric acid transport by rat renal brush border membrane transporter(s) and basolateral Oat1 and Oat3. Effects of angiotensin II receptor blockers in rats may be mainly determined by their intrinsic effects (cis-inhibition and trans-stimulation) on uric acid reabsorption transporter(s) and their pharmacokinetic properties in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762713     DOI: 10.2133/dmpk.23.263

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  3 in total

Review 1.  Allopurinol, uric acid, and oxidative stress in cardiorenal disease.

Authors:  Markus Riegersperger; Adrian Covic; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2011-03-10       Impact factor: 2.370

2.  Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.

Authors:  Atsushi Hosomi; Takeo Nakanishi; Takuya Fujita; Ikumi Tamai
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

3.  Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.

Authors:  Kei Nishizawa; Noriaki Yoda; Fumi Morokado; Hisakazu Komori; Takeo Nakanishi; Ikumi Tamai
Journal:  PLoS One       Date:  2019-04-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.